BR9705125A - Determinação de cpsa - Google Patents

Determinação de cpsa

Info

Publication number
BR9705125A
BR9705125A BR9705125A BR9705125A BR9705125A BR 9705125 A BR9705125 A BR 9705125A BR 9705125 A BR9705125 A BR 9705125A BR 9705125 A BR9705125 A BR 9705125A BR 9705125 A BR9705125 A BR 9705125A
Authority
BR
Brazil
Prior art keywords
cpsa
determination
Prior art date
Application number
BR9705125A
Other languages
English (en)
Inventor
Zeqi Zhou
William Jeffrey Allard
Kwok K Yeung
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9705125A publication Critical patent/BR9705125A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
BR9705125A 1996-10-25 1997-10-23 Determinação de cpsa BR9705125A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73838396A 1996-10-25 1996-10-25
US83496997A 1997-04-07 1997-04-07

Publications (1)

Publication Number Publication Date
BR9705125A true BR9705125A (pt) 1999-04-06

Family

ID=27113355

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9705125A BR9705125A (pt) 1996-10-25 1997-10-23 Determinação de cpsa

Country Status (2)

Country Link
US (1) US5840501A (pt)
BR (1) BR9705125A (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
ES2323407T3 (es) 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
WO2002016598A2 (en) 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
AU8846601A (en) 2000-08-28 2002-03-13 Agensys Inc Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1565200A4 (en) 2002-11-27 2009-06-24 Agensys Inc NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
EP2343315A3 (en) 2003-02-10 2011-11-23 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
ES2384622T3 (es) 2003-05-30 2012-07-10 Agensys, Inc. Variantes del antígeno de células madre de próstata (PSCA) y subsecuencias de las mismas
EP1753871B1 (en) 2004-05-28 2015-07-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
CN101754812B (zh) 2007-05-04 2013-06-26 克拉洛诊断仪器公司 流体连接器和微流体系统
EP3278877B1 (en) 2009-02-02 2020-06-03 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
CA2866007C (en) 2012-03-05 2023-01-03 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
DE202015009668U1 (de) 2014-03-28 2019-01-21 Opko Diagnostics, Llc Zusammensetzungen zur Diagnose von Prostatakrebs
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
WO2017103047A1 (en) * 2015-12-17 2017-06-22 Institut Curie Use of antisense long non-coding rnas for the diagnosis of prostate cancer
WO2019211218A1 (en) 2018-05-02 2019-11-07 Hahn-Schickard-Gesellschaft Für Angewandte Forschung E. V. Immunoassay for an automated system
CN111175487A (zh) * 2020-02-27 2020-05-19 江苏泽成生物技术有限公司 一种复合前列腺特异性抗原试剂盒及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0690203B2 (ja) * 1985-08-23 1994-11-14 中外製薬株式会社 前立腺特異抗原とα▲下１▼−アンチトリプシン複合体の定量方法
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
DE4322342A1 (de) * 1993-07-05 1995-02-09 Gif Ges Fuer Immunologische Fo Verfahren für die Differentialdiagnostik des Prostata-Karzinoms
EP0635575A1 (en) * 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma

Also Published As

Publication number Publication date
US5840501A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
BR9705125A (pt) Determinação de cpsa
FR2745635B1 (fr) Determination des caracteristiques de fluides
DE69513300D1 (de) Bestimmungsverfahren
HUP9701717A3 (en) Determination of cpsa
DE69720722D1 (de) Leistungseffizienter empfänger
DE69704549D1 (de) Aufnahmevorrichtung
PT794378E (pt) Dispositivo de uniao
ATA203196A (de) Bauelement
DE59704994D1 (de) Kombinationsinstrument
PT927183E (pt) Inibidores espirociclicos de metaloproteases
FR2746875B1 (fr) Garniture de friction
DE59701655D1 (de) Bauelement
PT923594E (pt) Compostos de bromotiacumicina
BR9604371A (pt) Macrobiomembrana biossintética indutora de neoformação
PT876199E (pt) Cabeca misturadora de educao
ID16330A (id) Pembuatan asetaldehide
ID17978A (id) Pembuatan 6-aminokapronitril
DE29619780U1 (de) Entstörvorrichtung
ID17636A (id) Pembuatan 6-aminokapronitril
DE69705281D1 (de) Aschenbecher
FI960151A0 (fi) Instrumentti
DE29702567U1 (de) Bauelement
DE29610829U1 (de) Bauelement
BR9704770A (pt) Derivados de 1-carba-(detia)-cefalosporina
BR9708484A (pt) Aplicação de arilimidazóis substituídos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements